List of Excipients in Branded Drug ADRIAMYCIN

Generic Drugs Containing ADRIAMYCIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9275	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9369	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9369	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9369	WATER
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9549	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9549	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in ADRIAMYCIN?

# Of NDCs	Excipient
2	HYDROCHLORIC ACID
1	LACTOSE MONOHYDRATE
2	SODIUM CHLORIDE
2	WATER

Adriamycin Excipient Strategy and Commercial Opportunities in Doxorubicin

Last updated: August 5, 2026

Adriamycin is the original brand of doxorubicin hydrochloride, an anthracycline oncology drug whose active-ingredient and basic injectable-product exclusivity expired long ago. The commercial opportunity has shifted from protecting doxorubicin itself to improving stability, handling, tissue distribution, cardiotoxicity management, manufacturing efficiency, and outpatient administration. The strongest opportunities are liposomal and other depot delivery systems, ready-to-use presentations, low-shedding container systems, and formulation technologies that reduce occupational exposure.

What is Adriamycin and what formulation does it use?

Adriamycin is doxorubicin hydrochloride administered by intravenous infusion or injection. The conventional product is an acidic aqueous solution, generally supplied at a concentration of 2 mg/mL. The formulation uses sodium chloride as the tonicity agent and hydrochloric acid for pH adjustment. The product is preservative-free and intended for single-use administration.[1]

Attribute	Conventional Adriamycin/doxorubicin injection
Active ingredient	Doxorubicin hydrochloride
Drug class	Anthracycline topoisomerase II inhibitor
Primary route	Intravenous
Typical concentration	2 mg/mL
Formulation type	Acidic aqueous solution
Key formulation functions	Solubilization, pH control, isotonicity
Preservative	None in the cited single-dose presentation
Main clinical constraints	Cumulative cardiomyopathy, myelosuppression, extravasation, vesicant handling
Regulatory pathway for generics	Abbreviated New Drug Application, where pharmaceutical equivalence and bioequivalence requirements are met

The formulation is technically simple but operationally demanding. Doxorubicin is a hazardous cytotoxic drug, and the commercial value of an improved excipient system depends less on basic solubility than on containment, stability, dosing accuracy, administration time, and tissue exposure.

What excipients are used in conventional doxorubicin injection?

The conventional formulation uses a limited excipient package:

1. Sodium chloride supports isotonicity.
2. Hydrochloric acid adjusts and maintains the acidic pH.
3. Water for injection is the vehicle.

The low excipient burden reduces compatibility and regulatory complexity. It also limits differentiation. A follow-on product that uses the same aqueous formulation will generally compete on supply reliability, vial size, concentration, packaging, service, and price rather than on meaningful clinical performance.

The acidic environment is commercially relevant. Doxorubicin stability depends on pH, temperature, light exposure, container compatibility, and dilution conditions. A differentiated formulation must preserve chemical potency while avoiding precipitation, adsorption, degradation products, and changes in color or particulate burden during storage and administration.[1,2]

Which excipient risks affect doxorubicin products?

Key risks include:

• pH drift during long-term storage or dilution.
• Adsorption to tubing, bags, filters, or elastomeric components.
• Light sensitivity and visible color changes.
• Formation of subvisible particles.
• Extractables and leachables from primary packaging.
• Incompatibility with alkaline solutions.
• Increased degradation after dilution.
• Occupational exposure during reconstitution or transfer.
• Patient sensitivity to novel surfactants, lipids, polymers, or cosolvents.

For parenteral oncology products, excipient selection must meet more than ordinary pharmaceutical functionality. The excipient must have a suitable injectable safety history, acceptable impurity control, a defensible toxicological profile, and manufacturing controls appropriate for a cytotoxic product. FDA acceptance in an oral product does not automatically establish suitability for intravenous use.[3]

What formulation patents protect doxorubicin products?

The original composition-of-matter protection for doxorubicin is expired. Conventional doxorubicin injection therefore has limited patent-based barriers to generic entry.

The commercially relevant patent categories are:

Patent category	Typical subject matter	Current commercial importance
Conventional solution	pH, concentration, stability, packaging	Low to moderate
Liposomal delivery	Lipid composition, particle size, loading, release profile	High
Polymer or nanoparticle delivery	Encapsulation, targeting, controlled release	Moderate to high
Combination therapy	Doxorubicin with another active agent or cardioprotective treatment	Moderate
Manufacturing process	Drug loading, sterile processing, scale-up, purification	High as a trade-secret barrier
Method of use	Specific cancer subtype, dosing schedule, sequencing, patient selection	Moderate
Device and administration	Closed transfer, infusion systems, prefilled devices	Moderate

Doxil, the pegylated liposomal doxorubicin product, illustrates the value of delivery-system protection. Its formulation uses a liposomal carrier built around phospholipids, cholesterol, and a polyethylene glycol-linked lipid. The carrier changes circulation time, biodistribution, release behavior, and toxicity relative to conventional doxorubicin.[4]

A formulation patent is strongest when it claims a measurable technical result, such as a defined particle-size distribution, encapsulation efficiency, release profile, pharmacokinetic parameter, or reduced toxicity at a specified dose. Broad claims to "a liposome comprising doxorubicin" face greater validity and design-around risk because the field is mature and heavily populated with prior art.

When does Adriamycin lose exclusivity?

Adriamycin has already lost basic market exclusivity in the United States. FDA approval of doxorubicin hydrochloride injection dates to the 1970s, and multiple generic products have been approved.[1,5]

Exclusivity issue	Status
Active-ingredient patent	Expired
Conventional injectable formulation exclusivity	Expired
Generic doxorubicin injection	Established
Pediatric exclusivity for the original product	No current commercial significance
New formulation exclusivity	Product-specific and potentially available
New method-of-use exclusivity	Potentially available for a qualifying innovation
Biosimilar exclusivity	Not applicable

The relevant commercial question is no longer when Adriamycin loses exclusivity. It is whether a new doxorubicin delivery system can obtain independent protection and a regulatory pathway that supports premium pricing.

What is the FDA regulatory status of Adriamycin?

Doxorubicin hydrochloride injection is an FDA-approved prescription oncology product with a boxed warning for cardiomyopathy, severe myelosuppression, extravasation-related tissue injury, and other serious toxicities.[1]

The FDA-approved clinical uses include several hematologic malignancies and solid tumors. The label covers diseases such as breast cancer, lymphomas, sarcomas, and selected leukemias, subject to the product-specific prescribing information.

Conventional generic injections generally rely on an ANDA. A materially different delivery system may require a 505(b)(2) application or another product-specific pathway, depending on the extent of the difference and the reference product used. Liposomal doxorubicin cannot be treated as a routine generic solution because the carrier system changes product quality attributes, pharmacokinetics, distribution, and clinical performance.

What is the Orange Book status of Adriamycin?

The Orange Book is relevant for identifying approved reference-listed drugs, patents, and regulatory exclusivity. The original Adriamycin product does not have a live composition-of-matter exclusivity position that prevents generic doxorubicin injection.

Orange Book analysis remains product-specific. A sponsor evaluating a new formulation must separate:

• The reference product's listed patents.
• Patents associated with a different doxorubicin formulation.
• Method-of-use patents.
• Device or packaging patents.
• Unlisted manufacturing know-how.
• Patents that have expired, been disclaimed, or are unenforceable.

Doxorubicin is a small molecule, so biosimilar rules do not apply. A follow-on liposomal product is a generic or hybrid small-molecule product, not a biosimilar.

What excipient strategies create commercial opportunities?

1. Ready-to-use liquid presentations

A ready-to-use, appropriately concentrated product can reduce pharmacy compounding, transfer steps, and exposure risk. The value proposition is strongest in hospitals seeking to reduce preparation labor and improve closed-system handling.

Potential differentiators include:

• Multiple vial sizes aligned to common doses.
• Reduced overfill.
• Lower adsorption during dilution.
• Longer in-use stability.
• Compatibility with standard infusion materials.
• Barcoded, unit-dose packaging.
• Reduced preparation and administration time.

The main barrier is economic. A ready-to-use product must justify higher manufacturing and packaging costs against low-priced conventional generics.

2. Lyophilized or concentrated presentations

A lyophilized product may improve long-term stability or reduce shipping volume. It creates a larger excipient and manufacturing burden because the sponsor must optimize bulking agents, cryoprotectants, cake structure, reconstitution time, residual moisture, and container closure integrity.

Potential excipients include sugars, polyols, amino acids, or buffering agents. Each adds control requirements and may affect reconstitution, osmolality, degradation, and injectable tolerability.

This strategy is more attractive where the product must withstand extended distribution, intermittent demand, or storage conditions that challenge an aqueous solution.

3. Liposomal doxorubicin

Liposomal delivery has the clearest clinical and commercial differentiation. Doxil uses a pegylated liposome to alter pharmacokinetics and tissue distribution.[4]

The formulation platform can be optimized around:

• Lipid composition.
• PEG-lipid density.
• Particle size and polydispersity.
• Drug-to-lipid ratio.
• Encapsulation efficiency.
• Ammonium sulfate or other loading gradients.
• Release rate.
• Surface charge.
• Freeze-thaw and storage stability.

The commercial barrier is high. Liposomal products require specialized raw materials, aseptic processing, tight particle-size controls, validated loading procedures, and comparability studies. Manufacturing know-how may be as important as issued patent claims.

4. Non-PEG nanoparticles and depot systems

PEG alternatives may address concerns about anti-PEG antibodies, repeat-dose exposure, or long-term carrier accumulation. Candidates include biodegradable polymers, lipid-polymer hybrids, albumin-based carriers, and injectable depots.

These systems can support differentiated claims around controlled exposure, tumor accumulation, reduced peak plasma concentration, or reduced cardiotoxicity. They also create substantial development risk because the relationship between in vitro release and clinical performance may be difficult to establish.

5. Excipients aimed at cardiotoxicity reduction

Excipient changes alone cannot be assumed to reduce doxorubicin cardiotoxicity. The most credible strategy is to alter biodistribution or exposure rather than to claim that a conventional excipient directly protects the heart.

A sponsor may pursue:

• Lower cardiac exposure through encapsulation.
• Controlled release.
• Tumor-targeting ligands.
• Tumor-activated release.
• Combination with a separately approved cardioprotective agent.

Dexrazoxane is a cardioprotective drug, not a formulation excipient. Combining it with doxorubicin raises clinical, regulatory, and commercial questions distinct from excipient selection.

How strong is the patent estate for conventional doxorubicin?

The patent estate for standard doxorubicin injection is weak from a barrier-to-entry perspective. The active ingredient is old, the basic solution is well established, and generic competition is entrenched.

A new sponsor can improve patent strength by claiming a narrow but technically defensible package:

• A defined excipient ratio.
• A specified pH range tied to stability.
• A container closure system.
• A lyophilized cake with defined residual moisture.
• A liposome with defined size and loading characteristics.
• A release profile linked to pharmacokinetic performance.
• A manufacturing process that produces a critical quality attribute.
• A patient population or dosing schedule with clinical benefit.

The most defensible portfolio normally combines composition claims, process claims, product-by-process claims where permitted, and method-of-use claims. Process claims may be difficult to enforce against an imported finished product unless the process is central to the product's identity or can be established through testing.

Which companies are challenging or competing with Adriamycin?

The competitive field includes:

• Manufacturers of generic doxorubicin hydrochloride injection.
• Suppliers of pegylated liposomal doxorubicin.
• Oncology companies developing non-liposomal controlled-release systems.
• Contract development and manufacturing organizations with sterile lipid or nanoparticle capability.
• Hospital compounding and specialty-distribution providers competing on service and availability.

The conventional market is price-sensitive. The differentiated market is constrained by clinical evidence, manufacturing complexity, and payer acceptance.

Product strategy	Price pressure	Development cost	Patent opportunity	Clinical differentiation
Standard aqueous injection	Very high	Low to moderate	Low	Low
Ready-to-use injection	High	Moderate	Moderate	Operational
Lyophilized doxorubicin	Moderate	Moderate	Moderate	Stability and logistics
Pegylated liposomal product	Moderate	High	High	High
Targeted nanoparticle	Lower initially	Very high	High	Potentially high
Combination product	Variable	High	Moderate to high	Depends on evidence

What patent litigation and Paragraph IV risks affect doxorubicin?

Paragraph IV risk is limited for the original conventional injection because multiple generic products already compete in the market. It becomes more important when a sponsor launches a protected delivery system, particularly a liposomal product.

A Paragraph IV challenge may target:

• A formulation patent.
• A method-of-use patent.
• A manufacturing patent.
• A particle-size or release-profile claim.
• A patent listed for a reference-listed liposomal product.

Potential outcomes include early litigation, a settlement with a licensed launch date, a license with royalties, or a finding that the patent is invalid, not infringed, or unenforceable. A settlement agreement can materially affect launch timing even when the challenger has a strong noninfringement position.

For a new doxorubicin formulation, freedom-to-operate analysis should cover US, European, Japanese, Chinese, and other major oncology markets. Patent term, supplementary protection certificates, prosecution history, claim scope, and local patent litigation standards differ by jurisdiction.

What manufacturing and IP barriers matter most?

The main barriers are often technical rather than legal.

Manufacturing barriers

• Sterile filtration may be unsuitable for some nanoparticle systems.
• Lipid raw materials require tight purity and oxidation controls.
• Aseptic mixing and filling can alter particle size.
• Drug loading must be consistent across scale.
• Batch-to-batch release profiles require validated analytical methods.
• Cytotoxic containment increases facility and worker-protection costs.
• Freeze-drying can destabilize vesicles or change reconstitution behavior.

Intellectual-property barriers

• Prior art is extensive in liposomal anthracyclines.
• Broad carrier claims may be vulnerable.
• Patent term may be shorter than the clinical development timeline.
• Manufacturing know-how may not be visible in public patent documents.
• A formulation can avoid one patent family but encounter a separate process or method-of-use family.
• Global freedom to operate is more difficult than US clearance alone.

Trade secrets can protect lipid grades, loading conditions, mixing sequence, sterilization parameters, and scale-up controls. Trade-secret protection is valuable but does not prevent independent development.

What is the commercial outlook for Adriamycin excipient innovation?

The most attractive opportunities are products that solve a measurable hospital problem while preserving doxorubicin's established oncology utility.

Highest-priority opportunities

1. A ready-to-use product that reduces compounding steps and hazardous handling.
2. A stable, low-overfill presentation that reduces drug waste.
3. A liposomal or nanoparticle formulation with credible reduction in cardiac exposure.
4. A formulation compatible with closed-system transfer and common infusion platforms.
5. A lower-cost liposomal manufacturing process with comparable product performance.
6. A long-acting or tumor-targeted product supported by a defined clinical niche.

Revenue exposure

Revenue potential depends on the commercial segment:

• Standard injection: high unit volume but low margin.
• Hospital-ready presentation: modest premium with operational value.
• Liposomal formulation: higher price per dose but smaller eligible market and greater payer scrutiny.
• Targeted formulation: potentially large premium, offset by substantial clinical-development cost.
• Contract manufacturing: recurring revenue from formulation, sterile filling, and analytical services without full product commercialization risk.

A sponsor should not rely on the Adriamycin brand for pricing power. The brand's historic recognition does not create durable exclusivity where generic doxorubicin is available.

How does Adriamycin compare with Doxil?

Attribute	Conventional Adriamycin/doxorubicin	Doxil or comparable pegylated liposomal doxorubicin
Carrier	None	Pegylated liposome
Administration	Intravenous	Intravenous
Formulation complexity	Low	High
Generic substitution	Established for conventional products	Product-specific and more complex
Biodistribution	Conventional systemic exposure	Altered circulation and tissue distribution
Main differentiation	Cost and supply	Pharmacology, tolerability, and formulation
Manufacturing barrier	Moderate	High
Patent opportunity	Limited	Greater
Key risks	Cardiotoxicity, extravasation	Hand-foot syndrome, infusion reactions, carrier-related issues
Commercial positioning	Broad generic oncology use	Differentiated specialty oncology use

The comparison is not a simple substitution analysis. Doxil is not merely a more expensive version of conventional doxorubicin. Its carrier system changes product behavior and clinical use.

Key Takeaways

• Adriamycin is conventional doxorubicin hydrochloride injection, and its basic composition and formulation exclusivity have expired.
• Standard excipients are limited mainly to sodium chloride, hydrochloric acid, and water for injection.
• Conventional generic competition makes basic formulation innovation commercially weak.
• The strongest opportunities are ready-to-use products, long-stability presentations, liposomal systems, and targeted delivery technologies.
• Doxil demonstrates that the commercial value of doxorubicin can reside in the carrier, not the active ingredient.
• Patent strength depends on measurable formulation attributes, manufacturing controls, and clinically meaningful method-of-use claims.
• Biosimilar competition does not apply because doxorubicin is a small molecule.
• The principal barriers for advanced formulations are sterile manufacturing, analytical comparability, clinical evidence, and global freedom to operate.
• Commercial success requires a clear hospital, payer, or patient benefit that supports a premium over low-cost generic doxorubicin.

FAQs

Can a new excipient alone obtain patent protection for doxorubicin?

Usually not if the excipient is used in a conventional and predictable manner. Patentability improves when the excipient produces an unexpected stability, release, compatibility, pharmacokinetic, or safety result.

Is pegylated liposomal doxorubicin interchangeable with Adriamycin?

No. The products differ in carrier system, pharmacokinetics, administration characteristics, labeling, and clinical risk profile. Substitution depends on the specific product and applicable regulatory requirements.

Can a doxorubicin formulation qualify for three years of FDA exclusivity?

A new clinical investigation essential to approval of a qualifying change may support three-year exclusivity under the applicable FDA framework. The result depends on the product, application type, investigation, and approved change.

What excipients are most relevant for a doxorubicin nanoparticle?

Relevant classes include phospholipids, cholesterol, PEG-lipids, biodegradable polymers, stabilizing sugars, buffering agents, and surfactants. Selection depends on loading method, release profile, particle-size control, toxicity, and route of administration.

Does a formulation patent block generic doxorubicin injection?

A valid, enforceable formulation patent may block the patented formulation or a product that infringes its claims. It normally does not block an unclaimed conventional aqueous injection.

References

1. U.S. Food and Drug Administration. (2023). Adriamycin PFS (doxorubicin hydrochloride injection) prescribing information. FDA.

2. United States Pharmacopeia. (2024). Doxorubicin hydrochloride monograph. In United States Pharmacopeia and National Formulary.

3. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (2023). Doxil (doxorubicin hydrochloride liposome injection) prescribing information. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.